What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist - a synthetic peptide that mimics the action of the naturally occurring hormone GLP-1 in the body. Originally developed for the treatment of type 2 diabetes, semaglutide gained widespread attention after clinical trials demonstrated remarkable efficacy for weight management. It is one of the most rigorously studied peptide therapies available, with extensive clinical trial data supporting its use.
The peptide is available under several brand names for different indications. For weight management, it has been FDA-approved at a specific dose for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. For type 2 diabetes, it is approved at different doses. The compounded form of semaglutide is also available through licensed compounding pharmacies under physician prescription.
Semaglutide represents a significant advancement in the treatment of obesity - a chronic metabolic disease that affects over 40% of American adults. Unlike previous weight loss medications that often produced modest results with significant side effects, semaglutide has demonstrated the ability to produce substantial, sustained weight loss when combined with lifestyle modifications.
How Semaglutide Works
Semaglutide works by binding to GLP-1 receptors throughout the body, triggering several complementary mechanisms that support weight management. In the brain, it acts on appetite regulation centers - particularly the hypothalamus - to reduce hunger and increase feelings of fullness (satiety). Patients often describe a fundamental shift in their relationship with food, reporting reduced cravings and the ability to feel satisfied with smaller portions.
In the gastrointestinal tract, semaglutide slows gastric emptying, meaning food stays in the stomach longer. This contributes to prolonged satiety after meals and reduced caloric intake. In the pancreas, it enhances glucose-dependent insulin secretion and suppresses glucagon release, improving blood sugar regulation. These metabolic effects contribute to improved insulin sensitivity and reduced cardiovascular risk factors.
Semaglutide has been engineered with a fatty acid chain that allows it to bind to albumin in the blood, extending its half-life to approximately one week. This is what enables once-weekly dosing - a significant convenience factor compared to medications requiring daily administration. The sustained receptor activation provides consistent appetite suppression and metabolic benefits throughout the dosing interval.
Clinical Trial Results
Semaglutide has one of the most robust clinical evidence bases of any weight management therapy. The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program included multiple large-scale, randomized, double-blind, placebo-controlled trials involving thousands of participants. The results have been published in top-tier medical journals including the New England Journal of Medicine.
In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly achieved an average weight loss of approximately 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. Many participants achieved weight loss of 15-20% or more. The STEP 2 trial in patients with type 2 diabetes showed average weight loss of 9.6%. Across the STEP program, semaglutide consistently demonstrated significant improvements in waist circumference, blood pressure, lipid profiles, and glycemic markers.
Long-term data from the STEP 5 trial showed that weight loss was maintained over a 2-year treatment period, with participants sustaining an average loss of approximately 15.2% of body weight. These results represent a substantial improvement over historical pharmacological approaches to weight management and approach the outcomes previously achievable only through bariatric surgery.
Benefits Beyond Weight Loss
While weight loss is the primary outcome that draws patients to semaglutide, the benefits extend well beyond the number on the scale. Clinical trials have documented significant improvements in cardiometabolic risk factors including reductions in blood pressure, improvements in cholesterol profiles (higher HDL, lower triglycerides), reduced inflammatory markers, and improved glycemic control. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events.
Patients frequently report quality-of-life improvements that include increased energy levels, better sleep, improved mobility, reduced joint pain related to excess weight, and enhanced self-confidence. Many patients describe a reduction in food preoccupation and emotional eating patterns, which contributes to a healthier overall relationship with food.
Emerging research is also exploring potential benefits of GLP-1 receptor agonists for non-alcoholic fatty liver disease (NAFLD), obstructive sleep apnea, and neurodegenerative conditions. While these applications are still under investigation, the breadth of potential benefits reflects the systemic impact of improved metabolic health.
Dosing and Administration
Semaglutide for weight management is administered as a once-weekly subcutaneous injection. The dosing follows a gradual escalation protocol to minimize gastrointestinal side effects. Treatment typically begins at 0.25 mg weekly for the first four weeks, then increases in increments every four weeks through 0.5 mg, 1.0 mg, 1.7 mg, and ultimately to the maintenance dose of 2.4 mg weekly.
The injection is administered in the abdomen, thigh, or upper arm using a small-gauge needle. Most patients find the injection process straightforward after initial instruction. The injection can be given on any day of the week, at any time of day, with or without food - though it should be given on the same day each week for consistency.
Your physician may adjust the escalation timeline based on your tolerance and response. Some patients require a slower titration if gastrointestinal side effects are significant. The goal is to reach the therapeutic dose at a pace that balances efficacy with tolerability. Compounded semaglutide dosing may differ slightly from brand-name formulations, and your prescribing physician will determine the appropriate protocol for your situation.
Side Effects and Considerations
The most common side effects of semaglutide are gastrointestinal in nature. Nausea is reported by approximately 40-45% of patients in clinical trials, though it is typically mild to moderate and tends to improve after the first few weeks of treatment. Other GI side effects include diarrhea, constipation, vomiting, and abdominal discomfort. The gradual dose escalation protocol is specifically designed to minimize these effects.
Less common side effects include headache, fatigue, dizziness, and injection site reactions. Rare but serious potential risks include pancreatitis, gallbladder disease (including gallstones), and potential thyroid effects. In animal studies, semaglutide was associated with thyroid C-cell tumors, leading to a boxed warning against use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Semaglutide is contraindicated in patients with a history of medullary thyroid carcinoma, MEN2 syndrome, known hypersensitivity to semaglutide, and during pregnancy. Patients with a history of pancreatitis, gallbladder disease, or severe gastrointestinal conditions should discuss risks with their physician. Your GetPepWell physician will review your complete medical history to ensure semaglutide is safe for you.
Who Should Consider Semaglutide?
Semaglutide for weight management is appropriate for adults with a BMI of 30 or greater (obesity) or a BMI of 27 or greater (overweight) with at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea. It is intended for use in conjunction with a reduced-calorie diet and increased physical activity - not as a standalone solution.
Ideal candidates are individuals who have attempted to lose weight through lifestyle modifications alone without achieving adequate results. Semaglutide is not intended for cosmetic weight loss in individuals at a healthy weight. It is a medical treatment for a chronic metabolic condition, and appropriate patient selection is essential for both safety and efficacy.
At GetPepWell, your physician will evaluate your BMI, medical history, current medications, and weight management goals during your consultation. If semaglutide is appropriate, you will receive a prescription, comprehensive dosing instructions, dietary guidance, and ongoing physician monitoring throughout your treatment.